AstraZeneca Group plc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 111 Posts
1 2 3 ... 7
Citi Sees Advantage For Tesaro Despite Broad Lynparza Label
Article By: The Fly Friday, August 18, 2017 6:00 AM EDT
Citi analyst Robyn Karnauskas says the "broad label" given yesterday to AstraZeneca's Lynparza increases competition for Tesaro.
In this article: AZN, TSRO Also: CLVS
AstraZeneca Plunges Following Failed Lung Cancer Study
Article By: The Fly Thursday, July 27, 2017 2:34 PM EDT
Shares of AstraZeneca are dropping sharply after the company said its MYSTIC trial failed to show its two-drug combination extended progression-free survival compared with standard-of-care chemotherapy for lung cancer patients.
In this article: AZN Also: MRK, TEVA, BMY
AstraZeneca Says Phase III MYSTIC Trial Did Not Meet Primary Endpoint
Article By: The Fly Thursday, July 27, 2017 7:29 AM EDT
The combination of Imfinzi and tremelimumab did not meet the primary endpoint of improving PFS compared to SoC in patients whose tumors express PD-L1 on 25% or more of their cancer cells.
In this article: AZN
Three Large Cap Pharma Stocks To Buy Now
Article By: Zacks Investment Research Wednesday, July 12, 2017 5:20 AM EDT
While investors might think that the uncertainty of health care reform would bring volatility into the sector, we’ve actually seen healthcare stocks have a pretty decent year so far. The overall “Medical” sector is up about 11.9% year-to-date.
In this article: AZN, BAYRY, HLUYY
Hot Options Report: End Of Day - Monday, July 10
Article By: The Options Insider Monday, July 10, 2017 10:29 PM EDT
Most active stock options for end of day Monday: BAC, ASH, X, CSX, ICE, AAPL, CBI, NVDA and AZN.
In this article: ASH, AZN, BAC, CBI, CSX, ICE, X, AAPL, NVDA
Week In Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid
Article By: ChinaBio® Today Saturday, July 1, 2017 7:14 PM EDT
Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinovac is a Beijing vaccine company with legacy vaccines for hepatitis A and B.
In this article: AZN, GE, SVA, HCM
AstraZeneca: 4% Dividend Yield And A Pipeline To Emerging Market Growth
Article By: SureDividend Thursday, June 15, 2017 11:35 AM EDT
AstraZeneca’s strong pipeline and heavy presence in the emerging markets lay the groundwork for future growth.
In this article: AZN Also: JNJ, ABT
AstraZeneca Enters Agreement With Grunenthal To Divest Rights To Zomig
Article By: The Fly Wednesday, June 7, 2017 12:10 PM EDT
AstraZeneca announced that it has entered an agreement with Grunenthal for the global rights to Zomig outside Japan.
In this article: AZN, IPXL
Week In Review: Shanghai Pharma Considers $4 Billion Bid For Germany's Stada
Article By: ChinaBio® Today Saturday, May 20, 2017 11:46 AM EDT
Shanghai Pharma may bid $4 billion to acquire Stada Arzneimittel, a German generic drugmaker. Stada has already accepted a similar offer from a consortium formed by two private equity firms -- Bain and Cinven.
In this article: AZN, LLY
E AstraZeneca Achieves Positive Phase 3 Results In Late Stage Cancer Trial
Article By: Terry Chrisomalis Sunday, May 14, 2017 3:52 AM EDT
On Friday, AstraZeneca announced that it had achieved positive results in a phase 3 lung cancer study. The key drug used in the trial, Imfinzi, was shown to greatly cut the risk of death in lung cancer patients.
In this article: AZN Also: MRK
18 Drugs To Lose Patents In 2017; Could Jeopardize $26.5B For Big Pharma
Article By: Lorimer Wilson Saturday, April 22, 2017 8:24 PM EDT
With 18 branded drugs on the line, patent losses this year could jeopardize $26.5 billion in annual sales from Big Pharma, projected to be the biggest fall-off until at least 2025.
In this article: AZN, BMY, GSK, LLY, MRK, PFE, SNY, RHHBY, TEVA
Pharma Stock Roundup: Merck Gets CRL For Label Expansion Effort, Roche Cancer Drug Tops
Article By: Arpita Dutt Friday, April 14, 2017 12:00 PM EDT
It was a relatively slow week with key highlights including a complete response letter (CRL) for Merck’s label expansion efforts for its diabetes drugs and positive data on Roche’s lung cancer treatment.
In this article: AZN, JNJ, MRK, MYL, RHHBY, PFE, BMY
9 Blockbuster Drugs Making Their Debut In 2017; Total Revenue Expected To Be $16B By 2021
Article By: Lorimer Wilson Tuesday, April 11, 2017 11:56 PM EDT
It is always interesting to see what analysts believe the big new drugs of the year are going to be worth 5 years down the road and Clarivate Analytics has listed the 9 blockbusters their analysts expect to see approved by the FDA this year.
FDA Nixes Merck’s Request To Have Januvia Cardio Safety Data On Its Label
Article By: Lorimer Wilson Friday, April 7, 2017 12:10 PM EDT
Merck wanted to state on the label of their diabetes drug Januvia that patients could take it without raising their risk for cardio complications to distinguish themselves from same-class rivals like Onglyza, which has risks. FDA has nixed the idea.
In this article: AZN, MRK
Week In Review: Beijing's Creat Offers $1.3 Billion For Biotest Of Germany
Article By: ChinaBio® Today Saturday, April 1, 2017 12:27 PM EDT
Creat Group, a Beijing investment firm, has bid to acquire German blood plasma products maker Biotest for $1.3 billion (including debt).
In this article: AZN, JD
AstraZeneca Plc Receives Key Lung Cancer Drug Approval In China
Article By: Lorimer Wilson Saturday, March 25, 2017 11:58 AM EDT
AstraZeneca plc disclosed Friday via its official WeChat account that a key lung cancer drug has received approval from Chinese regulators, opening up a potentially very lucrative new market in a country where millions suffer from the disease.
In this article: AZN
1 to 16 of 111 Posts
1 2 3 ... 7